Breaking the 'Undruggable' Barrier: Nanoparticle-Based Combination Therapy Utilizing Sotorasib and PD-L1 Inhibitor for Treating Non-Small Cell Lung Cancer Patients with KRASG12C Mutations
Lung cancer is a highly prevalent and lethal type of cancer. Although targeted therapy and immunotherapy have received considerable attention in the treatment of lung cancer, particularly non-small cell lung cancer (NSCLC), there has been limited improvement in the overall recovery and survival rate...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
EDP Sciences
2025-01-01
|
| Series: | BIO Web of Conferences |
| Online Access: | https://www.bio-conferences.org/articles/bioconf/pdf/2025/25/bioconf_icbb2025_02009.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Lung cancer is a highly prevalent and lethal type of cancer. Although targeted therapy and immunotherapy have received considerable attention in the treatment of lung cancer, particularly non-small cell lung cancer (NSCLC), there has been limited improvement in the overall recovery and survival rates of lung cancer patients. Thus, there is currently a substantial need for more effective therapies for NSCLC. This study aimed to define a new approach for treating NSCLC by employing a nanoparticle-based strategy for co- delivering PD-L1 inhibitor and a targeted candidate, sotorasib. Sotorasib is a small molecule that specifically and irreversibly inhibits KRASG12C, which is the most prevalent KRAS mutation observed in non-small cell lung cancer (NSCLC). This indicates that the combination of targeted therapy with immunotherapy, resulting in a synergistic impact, holds promise as a potential treatment for NSCLC. |
|---|---|
| ISSN: | 2117-4458 |